期刊
PHARMACEUTICAL RESEARCH
卷 29, 期 8, 页码 2236-2248出版社
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s11095-012-0752-2
关键词
controlled nucleation; lipid nanoparticles; siRNA; zwitterionic lipids
资金
- NIH [2R01EB003008-08]
- Pfizer [QB3]
- Deutsche Forschungsgemeinschaft (DFG)
- NSF
- NIH NIGMS
We describe a nucleation-based method which allows for the generation of monodisperse lipid nanoparticles over a range of diameters. Using a set of novel zwitterionic lipids and inverse phosphocholine lipids with pKas ranging from 2 to 5, we showed how the hydrodynamic diameter of lipid nanoparticles can be systematically manipulated over a 60 nm to 500 nm size range. Lipid nanoparticles were prepared by adding an anti-solvent, such as water, to the organic phase containing the lipid components. This led to super-saturation and the spontaneous formation of particles. The growth and final particle size was controlled by the ratio of the components in the ternary system: lipid, organic solvent and aqueous phase. Particles with diameter below 125 nm were formed under conditions where the super-saturation coefficient was between 2.3 and 20. PEG-lipid served as an efficient growth inhibitor except at very high and low lipid concentrations. Encapsulation efficiency of siRNA into lipid nanoparticles was shown to be pH-dependent and requires the protonation of the anionic carboxylate groups of the zwitterionic lipids, emphasizing the importance of electrostatic forces. This process enables high encapsulation efficiency of nucleic acids and allows the size of lipid nanoparticles to be controlled.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据